What type of knee damage ChondroFiller injection treats

The most immediate question for anyone reading about ChondroFiller injection is whether it applies to their specific knee problem — because it does not suit every form of cartilage damage.

ChondroFiller injection is designed for focal, contained articular cartilage defects graded III or IV on the ICRS or Outerbridge scale. At Grade III, cartilage fibres are frayed and the damage extends more than halfway through the cartilage layer; at Grade IV, the full thickness is lost and subchondral bone is exposed. These are structurally significant lesions, but they are localised — a defined area of damage rather than widespread joint deterioration. Defect size up to approximately 6 cm² is within the treatable range; the scaffold fills a contained lesion, it does not resurface a joint.

The typical patient is someone with isolated cartilage damage — a sporting injury, a post-traumatic lesion following a previous knee accident, or early focal wear that has not spread across the joint surface. Crucially, the surrounding cartilage borders and the joint mechanics overall should be healthy. The scaffold relies on a healthy joint environment to work: progenitor cells recruited from the surrounding tissue migrate into the defect and progressively build repair tissue, a process that cannot occur reliably in a joint that is already broadly arthritic.

Advanced or diffuse osteoarthritis — where cartilage loss is widespread and bone-on-bone contact is the dominant finding — sits outside the scope of this treatment. Those patients are on a different care pathway, typically towards joint replacement rather than cartilage restoration.

For patients who fall between those two points — beyond what physiotherapy and pain management can adequately address, but not yet at the threshold for total knee replacement — a ChondroFiller injection may represent a meaningful joint-preservation option worth exploring with a consultant.

Who qualifies for ChondroFiller injection

Several clinical criteria need to align before a ChondroFiller injection is appropriate — and a consultant assessment is the only reliable way to confirm all of them.

Lesion confirmation

The defect should be confirmed on MRI or arthroscopy as a focal, well-defined cartilage lesion with intact surrounding borders. Imaging matters: a lesion that appears contained on symptoms alone may prove more extensive on scan, which changes the treatment conversation.

Stable joint mechanics

The knee must be mechanically sound. Significant ligamentous instability — an unaddressed ACL or MCL tear, for instance — or uncorrected malalignment would undermine the repair environment. Either issue would typically need addressing before, or alongside, any cartilage restoration work.

The outpatient injection pathway

The ultrasound-guided outpatient injection, which is the current treatment pathway at Lincolnshire Knee, is best suited to accessible lesions, particularly those at the smaller end of the treatable range. Larger or load-bearing defects may require a different protocol; the appropriate approach is determined at consultation, not by self-selection.

The clearest candidate

Patients who tend to be well suited are those with isolated cartilage damage — from a sporting injury, a previous knee accident, or focal early wear — whose symptoms are no longer adequately managed by conservative measures, and who have not yet reached the threshold for total knee replacement.

Specific age ranges, grading thresholds, and any requirements around prior treatments are not fixed rules: they are confirmed by the treating consultant at individual assessment.

How the ChondroFiller injection works

Understanding the mechanism helps explain why this injection can potentially support cartilage repair, rather than simply dampening pain as a steroid or hyaluronic acid injection would.

ChondroFiller is composed of acid-extracted Type I collagen — the same protein that forms the structural backbone of healthy articular cartilage. It is supplied as a liquid and delivered directly into the cartilage defect under ultrasound guidance, as an outpatient procedure under local anaesthesia. Once placed, it self-gels within three to five minutes, forming a dimensionally stable matrix that conforms to the shape of the defect. No bone drilling, no fibrin glue, and no surgical fixation are involved — the material sets in situ.

The scaffold itself contains no cells. Its role is structural: it provides a three-dimensional biological framework inside the defect — a ready-made environment that the body can work with. Progenitor cells from the surrounding synovium and subchondral bone migrate into this framework, attach, and gradually differentiate, replacing the degrading collagen matrix with native repair tissue over subsequent months. This process is known as acellular matrix-induced chondrogenesis. The device supplies the scaffold; the patient's own biology does the rebuilding.

Because no donor tissue is used and no cells need harvesting or laboratory processing, the entire procedure is single-step. There is no biopsy appointment, no cell culture wait, and no second operation — a meaningful difference from two-stage surgical techniques such as ACI or MACI.

ChondroFiller is a CE Class III medical device (Meidrix Biomedicals, Germany). It has been in clinical use across Europe for close to 20 years, across more than 19,000 procedures — an unusually long real-world track record for a regenerative scaffold of this type.

What outcomes the evidence supports

Published evidence for ChondroFiller injection in the knee centres on two headline figures: IKDC scores improve by approximately 30 points over 12 months — a shift that represents a clinically meaningful gain in both pain and function — and 70–85% of treated patients report meaningful symptom relief at three to five years.

Those numbers carry a clear qualification: they are drawn from aggregated smaller studies and European real-world registry experience accumulated over nearly two decades, not from a single large randomised controlled trial specific to the knee. That gap in the evidence base is worth stating plainly. It does not invalidate the outcome picture, but it does mean individual results may vary more than a large RCT would confirm.

The broader published picture — across joints and applications — supports both the biological mechanism and the safety profile. A 2025 prospective study (PMC12498443, n=59) found significantly better cartilage quality scores in ChondroFiller-treated patients versus controls at follow-up arthroscopy: median Outerbridge 1.5 versus 3.0 (P=0.006) and ICRS 1 versus 3 (P=0.002). That study was conducted following intra-articular fracture of the wrist, so it contributes evidence about scaffold performance and biological mechanism rather than direct knee efficacy data; the knee outcome figures above rest on the dedicated knee studies within the European evidence base. Across that evidence base as a whole — more than 19,000 procedures over close to 20 years — the recorded complaint rate is approximately 0.06%, a strong safety signal for a regenerative intervention of this type.

Outcomes in any individual case depend on defect size, lesion grade, the wider condition of the joint, and individual biology. A consultant assessment is the appropriate point at which those variables are weighed.

Getting ChondroFiller injection in Lincolnshire

Access to ChondroFiller injection in the UK sits entirely outside NHS provision. It is not commissioned by NHS England, is not covered by Bupa or AXA, and has no GP referral pathway — all access is self-funded private. Because there is no referral requirement and no waiting list, a consultant assessment can typically be arranged within days of making contact.

For Lincolnshire patients, local access is available through the Lincolnshire Knee Clinic and through MSK Doctors at The Keep Clinic, The Old Barracks, Sandon Road, Grantham (NG31 9AS). Both are part of the MSK Doctors group, which introduced ChondroFiller injection into UK practice through its London Cartilage Clinic on Harley Street under Professor Paul Y.F. Lee. Having a Lincolnshire provider means patients do not need to travel to London for assessment or treatment.

In terms of cost, UK private fees for ChondroFiller injection typically range from approximately £3,000 to £8,000 depending on defect size and individual circumstances. For comparison, surgical cartilage repair procedures such as ACI or MACI generally fall in the range of approximately £7,000–£14,000. Both figures should be treated as planning guides only — exact costs should be confirmed directly with the clinic before proceeding.

Patients who have researched other hydrogel injections available in Lincolnshire may come across Arthrosamid (a polyacrylamide gel offered by separate providers). Arthrosamid is a non-regenerative joint-cushioning treatment; ChondroFiller injection is a regenerative collagen scaffold pathway with a different biological aim. The two products address the knee in distinct ways and are not interchangeable.

Lincolnshire Knee Clinic is part of the MSK Doctors group and accepts patients without a referral. Assessments can be booked at lincolnshireknee.co.uk.

What to expect on the day and during recovery

On the day itself, no special preparation is required. There is no overnight stay and no theatre booking — most patients drive themselves home after a brief post-injection observation period at the clinic.

Normal daily activities can generally resume the following day: walking, desk work, and light household tasks present no obstacle. High-impact loading, running, and competitive sport are paused for approximately 2–4 weeks to allow the collagen scaffold to stabilise within the defect without excessive mechanical stress.

Cartilage matrix remodelling is a biological process, not a single event. Symptomatic improvement typically builds progressively over weeks to months — some patients notice a meaningful shift at around three months, while for others the change accumulates more gradually. Planning for that arc rather than expecting an immediate return to full function is the realistic mindset. Where a follow-up assessment is warranted, onMRI™ — an AI-assisted knee MRI analysis tool available through the group — can be used to evaluate scaffold integration and cartilage quality objectively. Specific milestones, including realistic timelines for returning to sport and higher-impact activity, are best confirmed with the consultant once early recovery is established.